To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03535740
Title A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (ALTA-2)
Acronym ALTA-2
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Ariad Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | SWE | NLD | ITA | FRA | ESP | DEU | CAN | AUT | AUS